Engineering for Equivalency: Building Reliable, Optimized Facilities Through Centralized Design Governance

[Article Title]

Biopharmaceutical manufacturing has become more complex and faster paced, increasing demands on facility design, scale-up, and lifecycle management. For CDMOs, ensuring consistency across sites is now as important as speed and regulatory compliance.

To address this, Samsung Biologics has adopted a centralized engineering governance model. Rather than managing projects in isolation, the company applies a unified engineering framework across all facilities, aligning processes, mechanical and electrical systems, HVAC, and utilities under a single governance structure. This approach supports regulatory consistency, reproducibility, and predictable performance, while standardized procedures and communication channels enhance coordination and reduce variability between sites.

Download this article to learn more about this approach and how it deploys standardized, regulatory-aligned facilities that achieve consistent performance across a global network.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.